Theresa Jizba

Dr. Theresa Jizba

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Journal of Professional Nursing
Verified
Journal Article
Closed access
TGToni L. Glover
Toni L. Glover
OEOlga Ehrlich
Olga Ehrlich
ADAndra Davis
Andra Davis
MLMegan Lippe
Megan Lippe
CCCarrie L. Cormack
Carrie L. Cormack
SMSusan Meskis
Susan Meskis

6 September 2022 in Nurse Educator
Verified
Journal Article
Closed access
TJTheresa Jizba
Theresa Jizba
LILindsay Dnp Iverson
Lindsay Dnp Iverson
AHAlexander Hall
Alexander Hall

4 April 2023 in Journal of Professional Nursing
Verified
Journal Article
Closed access
MPMeghan Potthoff
Meghan Potthoff
AKAmanda J. Kirkpatrick
Amanda J. Kirkpatrick
TJTheresa Jizba
Theresa Jizba

30 August 2024 in Nurse Educator
Verified
Journal Article
Closed access
TJTheresa Jizba
Theresa Jizba
LILindsay Dnp Iverson
Lindsay Dnp Iverson
AHAlexander Hall
Alexander Hall
CCCarrie Dnp Cormack
Carrie Dnp Cormack
EPElena Dnp Prendergast
Elena Dnp Prendergast

28 November 2023 in Baylor University Medical Center Proceedings
Verified
Journal Article
Closed access
TJTheresa Jizba
Theresa Jizba
Faran AhmadFaran Ahmad
Faran Ahmad
RWRyan W. Walters
Ryan W. Walters
PFPamela A. Foral
Pamela A. Foral
Christopher J. DestacheChristopher J. Destache
Christopher J. Destache
MVManasa Velagapudi
Manasa Velagapudi
Metronidazole treats obligate anaerobic bacterial and protozoal infections, with an elimination half-life of around 8 hours. The long elimination half-life, the favorable ratio of steady-state serum levels to minimum inhibitory concentration, and the presence of active metabolites have led to the consideration of metronidazole use at 12-hour dosage intervals. This systematic review aimed to compare the clinical outcomes of twice-daily and thrice-daily metronidazole dosing. Using the PRISMA checklist, we searched five databases to systematically identify all relevant studies published up to June 16, 2023. The final analysis included two published retrospective cohort studies of hospitalized adult patients: a single site study (n = 200) and a multisite study (n = 85) of "good" quality, as measured by the Newcastle-Ottawa scale. The reported baseline characteristics of the 8-hour and 12-hour dosing groups were comparable, and neither study identified significant differences in primary and secondary clinical outcomes. Metaanalysis of the need to escalate antibiotic therapy also showed no statistically significant differences using the Mantel-Haenszel fixed-effect method (95% confidence interval: 47.6% lower to 6.4 times higher risk, P = 0.34) and inverse-variance method (risk ratio: 1.87; 95% confidence interval: 0.52-6.65, P = 0.34). This review suggests that dosing metronidazole every 12 hours is as effective as every-8-hour dosing for hospitalized patients with anaerobic infections. These encouraging findings would benefit from validation by a multicenter randomized controlled trial since there would be many benefits to a 12-hour dosing interval while achieving similar clinical outcomes with traditional dosing. The studies in this systematic review excluded patients with Clostridioides difficile and central nervous system and amebiasis infections, so the findings do not apply to these infection types.

19 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
TJTheresa Jizba
Theresa Jizba
FAFaran Ahmad
Faran Ahmad
RWRyan W. Walters
Ryan W. Walters
PFPamela Foral
Pamela Foral
Christopher J. DestacheChristopher J. Destache
Christopher J. Destache
MVManasa Velagapudi
Manasa Velagapudi
Background. Metronidazole treats obligate anaerobic bacterial and protozoal infections, with an elimination half-life of around eight hours. The long elimination half-life, the favorable ratio of steady-state serum levels to minimum inhibitory concentration, and the presence of active metabolites lead to consideration of metronidazole use at 12-hour dosage intervals. This systematic review aimed to compare the clinical outcomes of twice-daily and thrice-daily metronidazole dosing. Methods. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. PubMed, Scopus, Science Direct, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials to systematically identify all relevant studies published up to June 16, 2023. Results. The final analysis included two published retrospective cohort studies; a single site (n = 200) and a multisite study (n = 85) of ‘good’ quality, as measured by the Newcastle-Ottawa scale. The reported baseline characteristics of the 8-hour and 12-hour dosing groups were comparable, and neither study identified significant differences in primary and secondary clinical outcomes. Meta-analysis of the need to escalate antibiotic therapy also showed no statistically significant differences using the Mantel-Haenszel fixed-effect method (95% CI: 47.6% lower to 6.4 times higher risk, p = 0.342) and inverse-variance method (RR: 1.87, 95% CI: 0.52-6.65, p = 0.336). Conclusions. Dosing metronidazole every 12 hours is as effective as every 8-hour dosing for anaerobic infections. Healthcare systems may consider the adoption of every 12-hour metronidazole dosing with continued evaluation of patient outcomes.